Skip to main content

Table 1 Genomic and transcript biomarkers significant in the discovery cohort

From: AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Variable Cell Population
Biomarker Value MNCs Blasts
Complete Response, CR OR (95% CI) P OR (95% CI) P
FLT3-ITD AR Continuous 0.61 (0.27–1.36) 0.229 0.92 (0.75–1.14) 0.446
≥ 0.5 vs. < 0.5 1.15 (0.38–3.51) 0.801 0.83 (0.24–2.84) 0.770
NPM1 Mutated vs. not 1.38 (0.74–2.59) 0.310 1.43 (0.76–2.72) 0.270
ERG1 Cont. 0.94 (0.88–1.00) 0.042 0.94 (0.90–0.99) 0.018
IQR 0.73 (0.54–0.99) 0.63 (0.43–0.93)
EVI1 Binary 0.46 (0.24–0.89) 0.020 0.38 (0.19–0.76) 0.006
Cont. 0.99 (0.98–1.00) 0.196 0.99 (0.98–1.01) 0.257
IQR 1.00 (1.00–1.00) 1.00 (1.00–1.00)
KIT Cont. 0.96 (0.91–1.01) 0.145 0.94 (0.88–0.99) 0.022
IQR 0.84 (0.67–1.06) 0.73 (0.56–0.95)
MN1 Cont. 0.99 (0.98–1.00) 0.064 0.99 (0.98–1.00) 0.020
IQR 0.86 (0.73–1.01) 0.78 (0.63–0.96)
Overall Survival, OS HR (95% CI) P HR (95% CI) P
FLT3-ITD AR Continuous 1.45 (1.03–2.06) 0.035 1.08 (0.98–1.19) 0.133
≥ 0.5 vs. < 0.5 1.05 (0.56–1.97) 0.879 0.92 (0.47–1.81) 0.807
NPM1 Mutated vs. not 1.10 (0.77–1.57) 0.610 1.04 (0.73–1.50) 0.820
CCNA1 Cont. 1.00 (1.00–1.00) < 0.001 1.00 (1.00–1.00) 0.020
IQR 1.08 (1.03–1.14) 1.07 (1.01–1.13)
ERG1 Cont. 1.04 (1.01–1.07) 0.020 1.04 (1.01–1.07) 0.002
IQR 1.21 (1.03–1.41) 1.36 (1.12–1.64)
EVI1 Binary 1.59 (1.10–2.29) 0.014 2.03 (1.39–2.96) < 0.001
Cont. 1.01 (1.00–1.01) 0.017 1.01 (1.00–1.01) 0.004
IQR 1.00 (1.00–1.00) 1.00 (1.00–1.00)
FLT3 Cont. 1.02 (1.00–1.03) 0.013 1.02 (1.00–1.03) 0.026
IQR 1.14 (1.03–1.27) 1.13 (1.01–1.26)
IL3RA Cont. 1.02 (0.99–1.05) 0.128 1.03 (1.00–1.06) 0.044
IQR 1.08 (0.98–1.19) 1.11 (1.00–1.22)
Relapse-Free Survival, RFS HR (95% CI) P HR (95% CI) P
FLT3-ITD AR Continuous 0.99 (0.30–3.30) 0.983 1.19 (0.92–1.55) 0.187
≥ 0.5 vs. < 0.5 0.88 (0.40–1.94) 0.750 1.95 (0.77–4.94) 0.161
NPM1 Mutated vs. not 0.96 (0.60–1.52) 0.850 0.96 (0.59–1.54) 0.860
CCNA1 Cont. 1.00 (1.00–1.01) 0.004 1.00 (1.00–1.00) 0.083
IQR 1.20 (1.06–1.36) 1.10 (0.99–1.22)
EVI1 Binary 1.89 (1.14–3.13) 0.014 1.94 (1.13–3.32) 0.015
Cont. 1.01 (1.00–1.02) 0.004 1.02 (1.01–1.03) 0.003
IQR 1.00 (1.00–1.00) 1.00 (1.00–1.00)
IL3RA Cont. 1.02 (1.00–1.05) 0.092 1.03 (1.00–1.07) 0.050
IQR 1.09 (0.99–1.21) 1.12 (1.00–1.25)
  1. FLT3-ITD AR was analyzed both as a continuous variable (Cont.) and as a binary variable as defined by the ELN-2017 guidelines (≥0.5 vs. < 0.5). Transcript expression fold changes were analyzed both as unadjusted variables (Cont.) and adjusted (divided) by the interquartile range (IQR) of the corresponding expression variable in the discovery data. EVI1 was analyzed as a continuous and as a binary variable (expressed vs. not)